Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy
NCT00304070Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- May 2007
- Primary completion
- Dec 2015
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 4
01
Overview
Phase 3, open-label trial of Cisplatin micelle injection (HA132), pegylated liposomal doxorubicin, etoposide and mitotane in adrenocortical carcinoma (ACC) (3 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free Survival at 5 years. Started May 2007; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)pegylated liposomal doxorubicinetoposidemitotane
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00304070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304070.